Skyhawk's Huntington's therapy shows symptom gains in extended early-stage study
Skyhawk Therapeutics reported that its RNA-splicing drug candidate for Huntington's disease, SKY-0515, led to a 1.59-point improvement on a disease severity scale during an extension of a Phase 1/2 trial. The company plans to advance the therapy into pivotal development based on these results. The findings suggest potential symptomatic benefit in patients with the neurodegenerative condition.
Skyhawk Therapeutics’ investigational RNA-splicing modulator, SKY-0515, produced a modest but notable reduction in disease severity among Huntington’s patients during an extended Phase 1/2 evaluation. The 1.59-point improvement on a standard clinical scale, while preliminary, suggests the compound may address underlying splicing defects rather than merely masking symptoms. Huntington’s is a progressive, inherited neurodegenerative disorder with no disease-modifying therapies currently approved, so any signal of symptomatic benefit is closely watched. Based on these findings, the company intends to move SKY-0515 into pivotal trials, though larger, longer studies will be needed to confirm durability and safety. The results add to a growing pipeline of RNA-targeting approaches for neurological conditions.
If SKY-0515’s early benefit holds in larger trials, it could offer Huntington’s patients a new option to slow functional decline, potentially delaying disability and reducing caregiver burden. Families and clinicians may gain a tool to manage symptoms more effectively, while payers and healthcare systems could see long-term cost savings if progression is postponed. However, the effect size is small and unverified, so expectations should remain cautious until pivotal data emerge.